Journal of Clinical Oncology and Cancer Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Oncology and Cancer Research 44 7897 074717

ONCOLYTIC VIRUS INNOVATIONS

oncolytic viruses (OVs) is an emerging anticancer strategy that exploits the lytic nature of viral replication to reinforce the killing of malignant cells. OVs are often used as tools to directly induce neoplastic cell death and to trigger local and/or systemic immune responses to metastatic cancer in vivo  Variety of OVs are now being evaluated as potential treatments for cancer in clinical trials. In spite of being engineered to specifically target tumor cells, the security and off-target effects of OV therapy are a priority .  Despite the potential for adverse effects, clinical trials so far revealed relatively minimal adverse immune-related effects, like fever. With advances in our understanding of virus replication cycles, several novel OVs have emerged. Reverse genetic systems have facilitated the insertion of anticancer genes into a variety of OVs to further enhance their tumor-killing capacity. during this review, we highlight the recent advances in OV therapy for a variety of human cancers in in vitro and in in vivo animal studies. We further discuss the longer term of OVs as a therapeutic strategy for a variety of life-threatening cancers.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Clinical Sciences

Get the App